NASDAQ:MDXH - Nasdaq - BE0974461940 - Common Stock - Currency: USD
NASDAQ:MDXH (2/21/2025, 8:00:01 PM)
1.86
0 (0%)
The current stock price of MDXH is 1.86 USD. In the past month the price decreased by -6.53%. In the past year, price decreased by -47.9%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege and currently employs 300 full-time employees. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
MDXHEALTH
CAP Business Center, Rue d'Abhooz 31
Herstal LIEGE BE
Employees: 300
Company Website: https://mdxhealth.com/
Investor Relations: https://mdxhealth.com/investors/
Phone: 3243642070
The current stock price of MDXH is 1.86 USD.
The exchange symbol of MDXHEALTH is MDXH and it is listed on the Nasdaq exchange.
MDXH stock is listed on the Nasdaq exchange.
12 analysts have analysed MDXH and the average price target is 6.16 USD. This implies a price increase of 231.23% is expected in the next year compared to the current price of 1.86. Check the MDXHEALTH stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MDXHEALTH (MDXH) has a market capitalization of 50.76M USD. This makes MDXH a Micro Cap stock.
MDXHEALTH (MDXH) currently has 300 employees.
MDXHEALTH (MDXH) has a support level at 1.85 and a resistance level at 1.87. Check the full technical report for a detailed analysis of MDXH support and resistance levels.
The Revenue of MDXHEALTH (MDXH) is expected to grow by 27.93% in the next year. Check the estimates tab for more information on the MDXH EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MDXH does not pay a dividend.
MDXHEALTH (MDXH) will report earnings on 2025-02-26, after the market close.
MDXHEALTH (MDXH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.52).
The outstanding short interest for MDXHEALTH (MDXH) is 0.07% of its float. Check the ownership tab for more information on the MDXH short interest.
ChartMill assigns a fundamental rating of 2 / 10 to MDXH. MDXH may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months MDXH reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS increased by 33.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.37% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to MDXH. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 22.81% and a revenue growth 27.93% for MDXH